FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
复制标题

DOI:
10.18632/oncotarget.3279
复制
发表时间:
2015-04-20
期刊:
影响因子:
--
通讯作者:
Miura O
Miura O
中科院分区:
其他
文献类型:
--
作者:
Nogami A;Oshikawa G;Okada K;Fukutake S;Umezawa Y;Nagao T;Kurosu T;Miura O

文献摘要

参考文献

被引文献

相似文献

FLT3-ITD 和 FLT3-TKD 是急性髓系白血病 (AML) 中最常见的酪氨酸激酶突变,前者与不良预后相关。在这里,我们发现,在 FLT3-TKD (32D/TKD) 驱动的造血 32D 细胞中,PI3K 抑制剂 GDC-0941 或 Akt 抑制剂 MK-2206 比 FLT3-ITD (32D/ITD) 更有效地通过线粒体介导的内在途径诱导细胞凋亡,FLT3-ITD (32D/ITD) 会强力激活 STAT5。对 GDC-0941 和 MK-2206 的耐药性是通过在 32D/TKD 细胞中表达组成型激活的 STAT5 突变体 STAT5A1*6 获得的,而在 32D/ITD 细胞或表达 FLT3-ITD 的人白血病 MV4-11 细胞中,它被 STAT5 抑制剂匹莫齐特消除。 GDC-0941 或 MK-2206 在 32D/TKD 中比在 32D/ITD 中更明显地诱导 4EBP1 去磷酸化,这种去磷酸化分别被 STAT5A1*6 或匹莫齐特阻止或增强,并且与 eIF4E/eIF4G 复合物形成和 Mcl-1 表达的下调相关。此外,Mcl-1 的外源表达赋予 32D/TKD 细胞对 GDC-0941 和 MK-2206 的抗性。最后,在带有 FLT3-ITD 的原代 AML 细胞中证实,匹莫齐特增强 4EBP1 去磷酸化和 Mcl-1 下调,从而增强 GDC-0941 的细胞毒性。这些数据表明,FLT3-ITD 强烈激活 STAT5,通过 mTORC1/4EBP1/eIF4E 途径维持 Mcl-1 表达,从而保护用 PI3K/Akt 途径抑制剂处理的细胞免于凋亡。
FLT3-ITD and FLT3-TKD are the most frequent tyrosine kinase mutations in acute myeloid leukemia (AML), with the former associated with poor prognosis. Here, we show that the PI3K inhibitor GDC-0941 or the Akt inhibitor MK-2206 induced apoptosis through the mitochondria-mediated intrinsic pathway more efficiently in hematopoietic 32D cells driven by FLT3-TKD (32D/TKD) than FLT3-ITD (32D/ITD), which robustly activated STAT5. The resistance to GDC-0941 and MK-2206 was gained by expression of the constitutively activated STAT5 mutant STAT5A1*6 in 32D/TKD cells, while it was abrogated by the STAT5 inhibitor pimozide in 32D/ITD cells or FLT3-ITD-expressing human leukemic MV4–11 cells. GDC-0941 or MK-2206 induced dephosphorylation of 4EBP1 more conspicuously in 32D/TKD than in 32D/ITD, which was prevented or augmented by STAT5A1*6 or pimozide, respectively, and correlated with downregulation of the eIF4E/eIF4G complex formation and Mcl-1 expression. Furthermore, exogenous expression of Mcl-1 endowed resistance to GDC-0941 and MK-2206 on 32D/TKD cells. Finally, it was confirmed in primary AML cells with FLT3-ITD that pimozide enhanced 4EBP1 dephosphorylation and Mcl-1 downregulation to augment cytotoxicity of GDC-0941. These data suggest that the robust STAT5 activation by FLT3-ITD protects cells treated with the PI3K/Akt pathway inhibitors from apoptosis by maintaining Mcl-1 expression through the mTORC1/4EBP1/eIF4E pathway.
DOI: 10.1038/bcj.2013.63
发表时间: 2013-11-29
影响因子: 12.8
作者:
Hayakawa, F.;Sugimoto, K.;Harada, Y.;Hashimoto, N.;Ohi, N.;Kurahashi, S.;Naoe, T.
通讯作者: Naoe, T.
DOI: 10.18632/oncotarget.114
发表时间: 2010-06
期刊: Oncotarget
影响因子: --
作者:
Martelli AM;Evangelisti C;Chiarini F;McCubrey JA
通讯作者: McCubrey JA
DOI: 10.1016/j.canlet.2012.09.020
发表时间: 2013-02-01
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Jin, Linhua;Tabe, Yoko;Lu, Hongbo;Borthakur, Gautam;Miida, Takashi;Kantarjian, Hagop;Andreeff, Michael;Konopleva, Marina
通讯作者: Konopleva, Marina
DOI: 10.1182/blood-2013-01-481457
发表时间: 2013-08-29
期刊: BLOOD
影响因子: 20.3
作者:
Lu, Jing;Zavorotinskaya, Tatiana;Garcia, Pablo D.
通讯作者: Garcia, Pablo D.
DOI: 10.1186/1476-4598-9-292
发表时间: 2010-11-10
期刊: MOLECULAR CANCER
影响因子: 37.3
作者:
Chen, Weina;Drakos, Elias;Rassidakis, George Z.
通讯作者: Rassidakis, George Z.